Long-term follow-up study of SAT-3247 for Duchenne
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This is a long-term follow-up study for people with Duchenne muscular dystrophy who already took part in a previous SAT-3247 trial. It checks how safe and effective the treatment stays over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier SAT-3247-CL-101 study.
- You should be on the same dose of steroids (or none) as during that study.
- You should not have new serious health problems (like heart condition or major infection).
- You should not be planning any major surgeries in the next year.
- You must be able to swallow tablets (or take crushed tablets with food).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study is for people with Duchenne muscular dystrophy who have already completed an earlier trial of the study medicine. It aims to check the safety and effectiveness of the treatment over a longer period.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This trial tests a new daily pill called SAT-3247 for boys with Duchenne muscular dystrophy (DMD) who are still able to walk. The goal is to see if it can help slow muscle decline.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.